• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Glycomimetics Inc (NQ: GLYC )

    0.2961 -0.0085 (-2.79%)
    Streaming Delayed Price Updated: 3:15 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 292,209
    Open 0.3074
    Bid (Size) 0.2961 (8)
    Ask (Size) 0.2995 (6)
    Prev. Close 0.3046
    Today's Range 0.2941 - 0.3074
    52wk Range 0.2350 - 3.530
    Shares Outstanding 64,464,412
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
    Via InvestorPlace
    Why GlycoMimetics Stock is Trading Higher Monday
    On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company. 
    Via Benzinga

    Performance

    YTD
    -89.11%
    -89.11%
    1 Month
    +24.67%
    +24.67%
    3 Month
    -87.01%
    -87.01%
    6 Month
    -89.68%
    -89.68%
    1 Year
    -82.68%
    -82.68%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    $1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
    Via Benzinga
    Earnings Outlook For GlycoMimetics
    Via Benzinga
    GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    From GlycoMimetics, Inc.
    Via Business Wire
    GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
    From GlycoMimetics, Inc.
    Via Business Wire
    GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024
    Via InvestorPlace
    Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
    Via Benzinga
    Exposures Fossil Fuels
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
    Via Benzinga
    Topics Earnings
    Exposures Financial
    GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
    Via Benzinga
    Why Is Acutus Medical (AFIB) Stock Down 41% Today?
    Via InvestorPlace
    Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    From GlycoMimetics, Inc.
    Via Business Wire
    GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
    From GlycoMimetics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
    Via InvestorPlace
    GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Earnings Scheduled For March 27, 2024
    Via Benzinga
    GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.